Susan Jones
Medical · Longview, TXNPI 1265457741
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 654 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 39.5% of the total. Among medical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 654 payments — averaging $25.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Amgen$3K
- AstraZeneca$2K
- Lilly USA, LLC$822
- UCB, Inc.$812
- GSK$741
- plus $3K from 28 others
What the payments were for
- Food & beverage$16,280100%
- Education$670%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 252 | $6,453 |
| Amgen | 106 | $2,633 |
| AstraZeneca(2 entities) | 50 | $1,549 |
| Lilly USA, LLC | 39 | $822 |
| UCB, Inc. | 24 | $812 |
| GSK | 34 | $741 |
| Radius Health, Inc. | 19 | $436 |
| Johnson & Johnson | 15 | $350 |
| Aurinia Pharma U.S., Inc. | 9 | $305 |
| Mallinckrodt Hospital Products Inc. | 8 | $281 |
| Teva Pharmaceuticals USA, Inc. | 8 | $231 |
| Fresenius Kabi USA, LLC | 10 | $167 |
| Pfizer | 9 | $164 |
| Sanofi | 5 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $158 |
| Bioventus LLC | 5 | $134 |
| Collegium Pharmaceutical, Inc. | 7 | $121 |
| Novartis | 7 | $119 |
| Boehringer Ingelheim | 6 | $99 |
| Regeneron Healthcare Solutions, Inc. | 5 | $89 |
| Organon | 5 | $66 |
| Sandoz | 3 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Genentech USA, Inc. | 2 | $51 |
| ANI Pharmaceuticals, Inc. | 2 | $49 |
| Kaleo, Inc. | 3 | $45 |
| Octapharma USA, Inc. | 2 | $43 |
| Alk-abello, Inc | 1 | $35 |
| USWM, LLC | 1 | $30 |
| Shield Therapeutics Inc | 1 | $25 |
| Incyte Corporation | 1 | $23 |
| Grifols USA, LLC | 1 | $21 |
| Mylan Institutional Inc. | 1 | $17 |
| Forte Bio-pharma LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,347 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 86 | $587,499 |
| Enbrel SureclickEtanercept | 61 | $476,936 |
| RinvoqUpadacitinib | 63 | $399,266 |
| Enbrel MiniEtanercept | 28 | $206,196 |
| Cimzia (2 Pack)Certolizumab Pegol | 14 | $85,366 |
| OtezlaApremilast | 16 | $76,118 |
| Sulfasalazine | 519 | $14,451 |
| Hydroxychloroquine Sulfate | 458 | $12,114 |
| MethotrexateMethotrexate Sodium | 539 | $11,406 |
| Leflunomide | 281 | $9,437 |
| Gabapentin | 524 | $6,277 |
| Tizanidine Hcl | 382 | $5,237 |
| Duloxetine Hcl | 377 | $4,970 |
| Mycophenolate Mofetil | 31 | $3,249 |
| Celecoxib | 54 | $2,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $6,453 | $399,26663 claims |
| UCB, Inc.Cimzia (2 Pack) | $812 | $85,36614 claims |
| AmgenOtezla | $2,633 | $76,11816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,490 medical providers in Texas.
Other medical in Longview
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Courtney AldridgeSan Antonio$89K
- Janine ShinnDallas$84K
- Radha BernanderKaty$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.